(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The 15 Most Rousing TED Chats on Self-awareness - 2Figure out How to Augment the Advantages of a Web-based Degree
- 3Live long and loiter: Why NASA's ESCAPADE probes will wait a year in space before heading to Mars
- 4EU Commission slams Israel's death penalty law for Palestinians
- 5Israel launches new wave of attacks against Hezbollah in Beirut
- Earthquake in Indonesia kills at least 1 person and sets off small tsunami
- Roche breast cancer pill cuts risk of disease recurrence by 30% in trial
- Three killed as unfinished building collapses on church service in Ghana
- Toddler given just 3 years to live after strange symptoms makes full recovery
- Investigate These Retreats Well known With Seniors
- The Way to Fruitful Weight reduction: Individual Wellbeing Excursions
- Four countries to boycott Eurovision 2026 over Israel’s inclusion
- Former IRGC child executioner tells ‘Post’ how he became devout Christian dissident
- Katz alleges Army Radio workers misled High Court in bid to halt closure
